Home / Stocks / Indraprastha Medical Corp
INDRAMEDCO

Indraprastha Medical Corp Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹360.35

Change

+2.35 (0.66%)

Open

₹359.95

Prev. Close

₹358.0

Day High

₹363.75

Day Low

₹354.8

Volume Analysis

Traded

187,178

Delivered

110,759

Delivery %

59.17%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (28.7%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹373.41 ₹368.58 ₹364.46 ₹359.63 ₹355.51 ₹350.68 ₹346.56
Fibonacci ₹368.58 ₹365.16 ₹363.05 ₹359.63 ₹356.21 ₹354.1 ₹350.68
Camarilla ₹362.81 ₹361.99 ₹361.17 ₹359.63 ₹359.53 ₹358.71 ₹357.89

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-20.02%

1 Week

+7.17%

1 Month

+16.2%

3 Months

-2.53%

6 Months

+0.43%

1 Year

-32.11%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

22.61%

Net margin 12.41% × asset turnover 1.33x × equity multiplier 1.37x

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Indraprastha Medical Corp holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 74/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (33/100) is the weakest area to weigh before deciding. Strong 3-year EPS growth (28.7%).

TopFund Score — Fundamentals Quality

74/100 — Good

Data confidence: 74/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

87

Cash Flow

71

Corporate Governance

90

Institutional Ownership

33

Business Quality

78

Risk & Volatility

37

Liquidity

55

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Company clarifies no undisclosed information behind recent share volume increase.

Exchange has sought clarification from Indraprastha Medical Corporation Ltd on November 17, 2026, with reference to Movement in Volume.

Mr. Shivakumar Pattabhiraman ceased as Managing Director effective 4 November 2026.

We hereby submit copies of the public notice of the financial results published on 30th October 2026, in the Financial Express all India edition in …

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026 (S)
Sales + 317 306 315 348 350 325 334 365 381 372 365 406 413
Expenses + 267 259 266 281 286 273 272 292 310 310 304 326 335
Operating Profit 50 47 48 67 64 52 61 73 71 62 61 80 77
OPM % 16.0% 15.0% 15.0% 19.0% 18.0% 16.0% 18.0% 20.0% 19.0% 17.0% 17.0% 20.0% 19.0%
Other Income + 4 4 5 5 6 5 6 7 7 7 7 8 9
Interest 1 1 2 2 2 2 1 2 2 1 1 2 2
Depreciation 10 10 10 11 11 11 11 10 11 11 11 12 12
Profit before tax 44 41 42 60 57 45 55 68 66 56 55 75 72
Tax % 25.0% 28.0% 25.0% 25.0% 26.0% 26.0% 26.0% 25.0% 25.0% 27.0% 24.0% 25.0% 26.0%
Net Profit + 33 29 31 45 42 33 41 51 49 41 42 56 54
EPS in Rs 4 3 3 5 5 4 4 6 5 4 5 6 6
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 11 11 15 13 10 6 6 5 9 14 9 11 8

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Sales + 714 755 766 753 788 831 613 888 1,099 1,245 1,356 1,483
Expenses + 630 675 686 678 706 743 572 768 947 1,050 1,112 1,215
Operating Profit 85 80 79 74 82 87 41 120 152 195 245 267
OPM % 12.0% 11.0% 10.0% 10.0% 10.0% 11.0% 7.0% 14.0% 14.0% 16.0% 18.0% 18.0%
Other Income + 1 1 0 -1 -1 0 0 -3 9 16 22 28
Interest 8 7 8 9 7 6 3 3 4 4 6 6
Depreciation 28 35 31 31 30 33 33 35 39 40 44 44
Profit before tax 50 39 41 34 45 48 4 79 117 166 216 246
Tax % 34.0% 37.0% 36.0% 38.0% 36.0% 9.0% 46.0% 26.0% 26.0% 25.0% 26.0% 25.0%
Net Profit + 32 24 26 21 28 44 2 59 86 124 161 184
EPS in Rs 4 3 3 2 3 5 0 6 9 14 18 20
Dividend Payout % 51.0% 68.0% 63.0% 65.0% 52.0% 0.0% 0.0% 39.0% 32.0% 33.0% 26.0% 20.0%
Sales growth 5 6 1 -2 5 5 -26 45 24 13 9 9

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S) Sep 2026 (S)
Reserves 103 132 139 141 152 176 181 234 288 386 505 649 723
Borrowings + 50 52 67 66 21 4 3 5 2 34 33 37 35
Other Liabilities + 196 185 160 134 157 177 157 131 173 212 222 214 269
Total Liabilities 442 460 458 432 422 449 432 462 555 723 852 991 1,118
Fixed Assets + 286 301 296 294 280 303 283 277 275 347 328 365 387
CWIP 3 3 0 0 1 0 3 0 3 0 33 3 3
Investments 0 0 0 0 0 0 0 0 0 0 0 0 142
Other Assets + 153 157 163 138 141 146 145 185 278 376 491 624 586
Total Assets 442 460 458 432 422 449 432 462 555 723 852 991 1,118
Equity Capital 92 92 92 92 92 92 92 92 92 92 92 92 92

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Cash from Operating Activity + 64 62 28 48 75 86 27 94 144 200 157 167
Cash from Investing Activity + -29 -33 -22 -30 -17 -40 -19 -74 -108 -158 -111 -178
Cash from Financing Activity + -35 -30 -5 -17 -44 -43 -3 -3 -26 -32 -46 -46
Net Cash Flow 0 0 0 1 14 4 5 17 11 9 0 -57
Free Cash Flow 35 29 5 17 58 46 6 65 100 131 120 108
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 98 104 57 82 110 113 88 95 102 127 89 88

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 51.0% → 51.0%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 41.69% 43.01% 44.14% 43.16% 42.91% 42.5% 42.74% 43.08% 45.43% 45.69% 45.65% 44.83%
Promoters 51.0% 51.0% 51.0% 51.0% 51.0% 51.0% 51.0% 51.0% 51.0% 51.0% 51.0% 51.0%
FII 0.95% 1.08% 1.7% 2.64% 2.88% 2.94% 2.73% 2.41% 2.72% 2.43% 2.77% 2.39%
DII 6.36% 4.91% 3.14% 3.19% 3.18% 3.56% 3.56% 3.51% 0.82% 0.87% 0.59% 1.77%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Indraprastha Medical Corp (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Indraprastha Medical Corp?

Frequently Asked Questions about Indraprastha Medical Corp

Community Sentiment

What are other investors saying about Indraprastha Medical Corp?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.